Notch and Wnt Dysregulation and Its Relevance for Breast Cancer and Tumor Initiation
AbstractBreast cancer is the second leading cause of cancer deaths among women in the world. Treatment has been improved and, in combination with early detection, this has resulted in reduced mortality rates. Further improvement in therapy development is however warranted. This will be particularly important for certain sub-classes of breast cancer, such as triple-negative breast cancer, where currently no specific therapies are available. An important therapy development focus emerges from the notion that dysregulation of two major signaling pathways, Notch and Wnt signaling, are major drivers for breast cancer development. In this review, we discuss recent insights into the Notch and Wnt signaling pathways and into how they act synergistically both in normal development and cancer. We also discuss how dysregulation of the two pathways contributes to breast cancer and strategies to develop novel breast cancer therapies starting from a Notch and Wnt dysregulation perspective. View Full-Text
- Supplementary File 1:
ZIP-Document (ZIP, 18 KB)
Share & Cite This Article
Braune, E.-B.; Seshire, A.; Lendahl, U. Notch and Wnt Dysregulation and Its Relevance for Breast Cancer and Tumor Initiation. Biomedicines 2018, 6, 101.
Braune E-B, Seshire A, Lendahl U. Notch and Wnt Dysregulation and Its Relevance for Breast Cancer and Tumor Initiation. Biomedicines. 2018; 6(4):101.Chicago/Turabian Style
Braune, Eike-Benjamin; Seshire, Anita; Lendahl, Urban. 2018. "Notch and Wnt Dysregulation and Its Relevance for Breast Cancer and Tumor Initiation." Biomedicines 6, no. 4: 101.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.